Home > Resources > Whitepapers > Is It Time To Adjust The Pharma PDE Sales Force Optimization Model?

Is It Time To Adjust The Pharma PDE Sales Force Optimization Model?

The rise of performance-based managed care contracts is requiring pharma companies to demonstrate drug value in producing health outcomes and/or health economic benefits.1 While performance-based contracts are currently still relatively rare, even without these contracts, managed care plans are making decisions on formulates based on evidence of value. They are also looking to guidelines and the treatment pathways being adopted by providers which are also driven by evidence of outcomes and value.

Spotlight

Ajanta Pharma Ltd

Ajanta Pharma Limited (APL) is a pharmaceutical company headquartered in Mumbai, India. It has strong presence in Branded Generic business in India & Emerging markets; and Generic business in USA.In India, company operates in selected therapeutic areas of Cardiology, Dermatology, Ophthalmology and Pain management. Its brands in each of sub-therapeutic areas or molecules hold leadership positions.In Emerging Markets, company has presences in Africa, Asia, Middle East, and CIS on broader therapeutic segments such as anti-malarial, gastro, antibiotics, cardiology, dermatology, pain management, etc.

OTHER WHITEPAPERS

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.

Sales coaching: preparing for the new reality in pharma

whitePaper | October 14, 2022

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment.

New technology advances biopharma chromatography productivity

whitePaper | February 16, 2023

Monoclonal antibody drugs (mAbs) make up more than 50 percent of the biologics on the market today, as well as a significant number of new drugs in the development pipeline. The value and impact of these therapies has been dramatic.

Securing the modern pharmaceutical supply chain

whitePaper | April 22, 2022

Members of the Health-ISAC community have produced a security framework for the pharmaceutical supply chain comprising this CISO guide.

BUILDING A TOMORROW-READY LAB

whitePaper | September 8, 2022

Charles Darwin famously said on survival, "It is not the strongest of the species that survives, nor the most intelligent; it is the one most adaptable to change." Resilience has become an essential message in today's post-covid, next-normal world.

Application Notes & Whitepapers 2019

whitePaper | December 19, 2019

Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.

Is It Time To Adjust The Pharma PDE Sales Force Optimization Model?